In addition, menin inhibitors appear to have a synergistic effect with many other agents, such as venetoclax and FLT3 inhibitors, enhancing the effects of both classes of drugs and potentially improving outcomes in KMT2Ar and NPM1-mutated AML, especially in older patients and in those with R/R AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.